People living with HAE want to live a normal life.
Despite the substantial progress made in the past two decades,1 people living with HAE still have significant unmet need.2 They compromise between an effective therapy, its safety, or the ease of administration.3,4,5
Regardless of on-demand treatment or attack prevention, patients still experience stress, depression, and anxiety around their next attack.6 The burden of painful injections and the need for multiple doses to provide symptom relief results in 30-40% of HAE attacks not being completely resolved.7
Hereditary angioedema (HAE) is a rare and potentially life-threatening genetic disease that occurs in approximately 1 in 10,000 to 1 in 50,000 people, according to HAEi.
1 IN 10,000 – 50,000*
- USA 7,000-15,000* people
- EU 9,000-15,000* people
- Japan 2,500-4,500* people
Decreased production or production of functionally impaired C1 esterase inhibitor (C1-INH)
Generally passed on from parents to children
Living with HAE
Treatment of HAE consists of long-term prophylaxis, management of acute attacks, and intermittent episodic prophylaxis in advance of known triggers.
Multiple therapies are available, acting at different points in the bradykinin-forming cascade. Only one approved therapy, icatibant, acts directly at the bradykinin B2 receptor to treat all types of HAE by inhibiting bradykinin interaction with its bradykinin B2 receptor target, and hence by putting a halt to bradykinin-mediated signaling.
All current therapies, including icatibant, are limited by invasive routes of drug administration (injection or infusion), inconvenient dosing regimens, or undesired side effects. Surveys of people living with HAE overwhelmingly show that they seek additional treatment options.